| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hippocampus | 4 | 2018 | 237 | 2.33 | Why? |
| Biopterin | 2 | 2018 | 8 | 1.51 | Why? |
| Neopterin | 3 | 2019 | 69 | 1.46 | Why? |
| Corpus Striatum | 2 | 2019 | 49 | 0.90 | Why? |
| Amyloid Neuropathies | 1 | 2019 | 3 | 0.80 | Why? |
| Scabies | 1 | 2020 | 75 | 0.79 | Why? |
| Ubiquitin-Protein Ligases | 2 | 2021 | 249 | 0.79 | Why? |
| Physical Conditioning, Animal | 1 | 2019 | 31 | 0.78 | Why? |
| Lamivudine | 5 | 2018 | 210 | 0.77 | Why? |
| Memory, Long-Term | 1 | 2018 | 4 | 0.77 | Why? |
| HIV Infections | 18 | 2021 | 11620 | 0.76 | Why? |
| Homosexuality, Male | 5 | 2020 | 1158 | 0.74 | Why? |
| Avoidance Learning | 2 | 2018 | 99 | 0.74 | Why? |
| Sexually Transmitted Diseases, Viral | 1 | 2020 | 115 | 0.74 | Why? |
| Rome | 4 | 2021 | 497 | 0.72 | Why? |
| Uridine Monophosphate | 1 | 2017 | 41 | 0.71 | Why? |
| Eosinophil Cationic Protein | 1 | 2017 | 4 | 0.70 | Why? |
| Lymphogranuloma Venereum | 1 | 2017 | 23 | 0.69 | Why? |
| Basigin | 1 | 2020 | 276 | 0.69 | Why? |
| Anti-HIV Agents | 7 | 2018 | 2209 | 0.68 | Why? |
| Tryptases | 1 | 2017 | 37 | 0.68 | Why? |
| Poaceae | 1 | 2017 | 23 | 0.68 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.66 | Why? |
| Memory Consolidation | 1 | 2016 | 6 | 0.65 | Why? |
| Conditioning, Classical | 1 | 2016 | 12 | 0.65 | Why? |
| Long-Term Potentiation | 1 | 2016 | 19 | 0.65 | Why? |
| Running | 1 | 2019 | 153 | 0.64 | Why? |
| Sarcoma, Kaposi | 1 | 2017 | 97 | 0.64 | Why? |
| Nootropic Agents | 1 | 2016 | 23 | 0.64 | Why? |
| MicroRNAs | 3 | 2019 | 1787 | 0.64 | Why? |
| Repressor Proteins | 1 | 2018 | 232 | 0.64 | Why? |
| Diabetes Mellitus, Experimental | 1 | 2018 | 192 | 0.62 | Why? |
| Pollen | 1 | 2017 | 137 | 0.62 | Why? |
| Syphilis | 1 | 2020 | 318 | 0.61 | Why? |
| Atazanavir Sulfate | 4 | 2018 | 213 | 0.59 | Why? |
| Rhinitis, Allergic, Seasonal | 1 | 2017 | 121 | 0.59 | Why? |
| Oxidative Stress | 5 | 2019 | 2050 | 0.59 | Why? |
| Mitochondria | 8 | 2019 | 857 | 0.59 | Why? |
| Astrocytes | 1 | 2017 | 298 | 0.59 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.56 | Why? |
| HIV Protease Inhibitors | 3 | 2018 | 434 | 0.55 | Why? |
| Medication Adherence | 2 | 2021 | 1270 | 0.53 | Why? |
| Inflammasomes | 2 | 2017 | 710 | 0.53 | Why? |
| NF-E2-Related Factor 2 | 1 | 2017 | 373 | 0.53 | Why? |
| Muscle, Skeletal | 2 | 2019 | 915 | 0.51 | Why? |
| Insulin Resistance | 1 | 2019 | 669 | 0.50 | Why? |
| Furin | 1 | 2020 | 1054 | 0.50 | Why? |
| Papillomavirus Infections | 5 | 2019 | 861 | 0.49 | Why? |
| Cognition Disorders | 1 | 2018 | 574 | 0.49 | Why? |
| HIV-1 | 10 | 2019 | 3365 | 0.46 | Why? |
| Rats, Wistar | 7 | 2018 | 621 | 0.46 | Why? |
| Glutarates | 3 | 2008 | 7 | 0.45 | Why? |
| Neurons | 1 | 2017 | 864 | 0.44 | Why? |
| Nitric Oxide | 1 | 2018 | 769 | 0.44 | Why? |
| Papillomaviridae | 4 | 2019 | 404 | 0.43 | Why? |
| Delayed Diagnosis | 1 | 2020 | 1529 | 0.42 | Why? |
| Allergens | 1 | 2017 | 728 | 0.41 | Why? |
| Lipopolysaccharides | 3 | 2019 | 848 | 0.39 | Why? |
| Genotype | 6 | 2019 | 4697 | 0.38 | Why? |
| Rats | 7 | 2018 | 2764 | 0.38 | Why? |
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 2 | 2019 | 9 | 0.37 | Why? |
| STAT4 Transcription Factor | 2 | 2019 | 16 | 0.37 | Why? |
| Antiretroviral Therapy, Highly Active | 7 | 2018 | 952 | 0.36 | Why? |
| Multienzyme Complexes | 2 | 2017 | 43 | 0.36 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.36 | Why? |
| Dopamine | 2 | 2019 | 123 | 0.35 | Why? |
| Mice, Inbred C57BL | 5 | 2019 | 5542 | 0.35 | Why? |
| Epilepsy, Temporal Lobe | 2 | 2017 | 37 | 0.34 | Why? |
| Inflammation | 4 | 2019 | 13255 | 0.34 | Why? |
| Hyperglycemia | 1 | 2018 | 1363 | 0.33 | Why? |
| Behavior, Animal | 2 | 2018 | 136 | 0.32 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.30 | Why? |
| DNA, Viral | 4 | 2019 | 2521 | 0.28 | Why? |
| Cerebral Cortex | 2 | 2008 | 276 | 0.28 | Why? |
| Serine Endopeptidases | 1 | 2020 | 4606 | 0.27 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2019 | 1969 | 0.27 | Why? |
| Viral Load | 7 | 2021 | 15850 | 0.27 | Why? |
| Autoimmune Diseases | 1 | 2017 | 1996 | 0.26 | Why? |
| Darunavir | 2 | 2017 | 477 | 0.26 | Why? |
| Ritonavir | 5 | 2018 | 4212 | 0.26 | Why? |
| Polymorphism, Single Nucleotide | 5 | 2020 | 3607 | 0.25 | Why? |
| Mice, Knockout | 2 | 2018 | 1815 | 0.23 | Why? |
| Sexually Transmitted Diseases | 2 | 2020 | 694 | 0.22 | Why? |
| Reverse Transcriptase Inhibitors | 3 | 2018 | 309 | 0.22 | Why? |
| Electron Transport | 2 | 2018 | 20 | 0.21 | Why? |
| Polymorphism, Genetic | 2 | 2019 | 1074 | 0.21 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2019 | 6166 | 0.21 | Why? |
| Interleukin-10 | 2 | 2019 | 1409 | 0.21 | Why? |
| Condylomata Acuminata | 1 | 2020 | 62 | 0.21 | Why? |
| Genetic Association Studies | 3 | 2019 | 559 | 0.20 | Why? |
| Facial Neoplasms | 1 | 2020 | 51 | 0.20 | Why? |
| Mutation | 1 | 2020 | 12376 | 0.20 | Why? |
| Genetic Predisposition to Disease | 4 | 2019 | 4027 | 0.20 | Why? |
| Mice | 7 | 2021 | 21357 | 0.20 | Why? |
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 24 | 0.20 | Why? |
| Toothbrushing | 1 | 2019 | 40 | 0.19 | Why? |
| GTP Cyclohydrolase | 1 | 2018 | 2 | 0.19 | Why? |
| Drug Resistant Epilepsy | 2 | 2017 | 106 | 0.19 | Why? |
| Exome | 1 | 2020 | 207 | 0.19 | Why? |
| Alcohol Oxidoreductases | 1 | 2018 | 14 | 0.19 | Why? |
| Maze Learning | 1 | 2018 | 35 | 0.19 | Why? |
| Autophagy-Related Protein 5 | 1 | 2018 | 28 | 0.19 | Why? |
| Nitric Oxide Synthase | 1 | 2018 | 37 | 0.19 | Why? |
| Male | 34 | 2021 | 367725 | 0.18 | Why? |
| Anus Diseases | 1 | 2018 | 55 | 0.18 | Why? |
| Animals | 16 | 2021 | 78931 | 0.18 | Why? |
| Limbic System | 1 | 2017 | 14 | 0.18 | Why? |
| Serotonin | 1 | 2019 | 137 | 0.18 | Why? |
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2017 | 3 | 0.17 | Why? |
| Cyclohexanes | 1 | 2017 | 43 | 0.17 | Why? |
| Laser Therapy | 1 | 2020 | 158 | 0.17 | Why? |
| Neuronal Plasticity | 1 | 2018 | 98 | 0.17 | Why? |
| Glutathione Transferase | 1 | 2017 | 86 | 0.17 | Why? |
| Nevirapine | 1 | 2017 | 57 | 0.17 | Why? |
| Oropharyngeal Neoplasms | 1 | 2019 | 138 | 0.17 | Why? |
| Cell Transformation, Neoplastic | 2 | 2018 | 191 | 0.17 | Why? |
| Nasal Lavage Fluid | 1 | 2017 | 43 | 0.17 | Why? |
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 133 | 0.17 | Why? |
| CD4 Lymphocyte Count | 3 | 2018 | 1517 | 0.17 | Why? |
| Cytodiagnosis | 1 | 2018 | 104 | 0.17 | Why? |
| HIV Reverse Transcriptase | 1 | 2017 | 104 | 0.17 | Why? |
| Diabetic Neuropathies | 1 | 2017 | 64 | 0.17 | Why? |
| Pharmacogenomic Variants | 1 | 2017 | 112 | 0.17 | Why? |
| Locomotion | 1 | 2018 | 130 | 0.16 | Why? |
| HIV Protease | 1 | 2017 | 86 | 0.16 | Why? |
| Injections, Intraventricular | 1 | 2016 | 11 | 0.16 | Why? |
| Rectum | 1 | 2020 | 495 | 0.16 | Why? |
| Glycine | 1 | 2018 | 203 | 0.16 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.16 | Why? |
| Anus Neoplasms | 1 | 2018 | 123 | 0.16 | Why? |
| Microscopy, Confocal | 1 | 2017 | 343 | 0.16 | Why? |
| Pituitary Neoplasms | 1 | 2018 | 130 | 0.15 | Why? |
| Optical Imaging | 1 | 2017 | 197 | 0.15 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.15 | Why? |
| Chlamydia trachomatis | 1 | 2017 | 172 | 0.15 | Why? |
| Memory Disorders | 1 | 2017 | 190 | 0.15 | Why? |
| HIV | 2 | 2020 | 1116 | 0.15 | Why? |
| Microscopy, Electron, Transmission | 1 | 2018 | 605 | 0.15 | Why? |
| Raltegravir Potassium | 1 | 2016 | 132 | 0.15 | Why? |
| Sjogren's Syndrome | 1 | 2019 | 284 | 0.15 | Why? |
| Arginine | 1 | 2018 | 377 | 0.15 | Why? |
| Humans | 43 | 2021 | 930598 | 0.15 | Why? |
| Stevens-Johnson Syndrome | 1 | 2017 | 129 | 0.14 | Why? |
| Phenotype | 4 | 2020 | 4037 | 0.14 | Why? |
| Promoter Regions, Genetic | 1 | 2019 | 823 | 0.14 | Why? |
| Dermatologists | 1 | 2020 | 435 | 0.14 | Why? |
| Drug Therapy, Combination | 6 | 2018 | 7268 | 0.14 | Why? |
| Epithelial-Mesenchymal Transition | 1 | 2017 | 242 | 0.14 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.14 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.14 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.14 | Why? |
| Mouth Diseases | 1 | 2017 | 193 | 0.14 | Why? |
| Gracilaria | 1 | 2013 | 1 | 0.13 | Why? |
| AIDS Vaccines | 1 | 2019 | 452 | 0.13 | Why? |
| Mouthwashes | 1 | 2019 | 432 | 0.13 | Why? |
| RNA, Long Noncoding | 1 | 2019 | 408 | 0.13 | Why? |
| Uric Acid | 1 | 2017 | 285 | 0.13 | Why? |
| Mouth | 1 | 2019 | 622 | 0.13 | Why? |
| Triazoles | 1 | 2017 | 440 | 0.13 | Why? |
| Mast Cells | 1 | 2017 | 370 | 0.13 | Why? |
| Dipeptidyl Peptidase 4 | 1 | 2020 | 1061 | 0.13 | Why? |
| DNA Methylation | 1 | 2018 | 688 | 0.12 | Why? |
| Sofosbuvir | 1 | 2017 | 518 | 0.12 | Why? |
| Tenofovir | 1 | 2016 | 449 | 0.12 | Why? |
| Anti-Retroviral Agents | 2 | 2019 | 1099 | 0.12 | Why? |
| Calcium | 1 | 2017 | 708 | 0.12 | Why? |
| Lead | 1 | 2013 | 94 | 0.12 | Why? |
| Interleukin-1beta | 1 | 2017 | 992 | 0.12 | Why? |
| Thiobarbituric Acid Reactive Substances | 3 | 2010 | 20 | 0.12 | Why? |
| Rhodophyta | 1 | 2011 | 28 | 0.11 | Why? |
| Female | 27 | 2021 | 380317 | 0.11 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.11 | Why? |
| Cell Differentiation | 1 | 2017 | 1338 | 0.11 | Why? |
| Brain | 3 | 2017 | 5133 | 0.11 | Why? |
| Signal Transduction | 2 | 2018 | 7207 | 0.11 | Why? |
| Ultraviolet Rays | 2 | 2011 | 1272 | 0.11 | Why? |
| Palaemonidae | 1 | 2010 | 4 | 0.11 | Why? |
| Eosinophils | 1 | 2017 | 848 | 0.10 | Why? |
| Up-Regulation | 1 | 2018 | 2249 | 0.10 | Why? |
| Adult | 21 | 2021 | 244371 | 0.10 | Why? |
| Copper | 1 | 2013 | 288 | 0.10 | Why? |
| Carcinoma, Squamous Cell | 1 | 2018 | 902 | 0.10 | Why? |
| Proteins | 1 | 2017 | 921 | 0.09 | Why? |
| Cell Line, Tumor | 1 | 2017 | 3608 | 0.09 | Why? |
| Glutathione Peroxidase | 2 | 2011 | 83 | 0.09 | Why? |
| Energy Metabolism | 2 | 2018 | 451 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.09 | Why? |
| Amino Acid Metabolism, Inborn Errors | 1 | 2007 | 6 | 0.09 | Why? |
| Treatment Failure | 3 | 2018 | 2106 | 0.09 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.08 | Why? |
| Lipid Peroxidation | 2 | 2008 | 114 | 0.08 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.08 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2018 | 1380 | 0.08 | Why? |
| Skin Neoplasms | 1 | 2020 | 1679 | 0.08 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.08 | Why? |
| Early Detection of Cancer | 1 | 2018 | 1956 | 0.08 | Why? |
| Genotyping Techniques | 2 | 2019 | 360 | 0.08 | Why? |
| Parkinson Disease | 1 | 2018 | 1414 | 0.07 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.07 | Why? |
| Oxazines | 2 | 2017 | 279 | 0.07 | Why? |
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 1692 | 0.07 | Why? |
| RNA, Messenger | 1 | 2019 | 5131 | 0.07 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.07 | Why? |
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 275 | 0.07 | Why? |
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 502 | 0.07 | Why? |
| Piperazines | 2 | 2017 | 445 | 0.07 | Why? |
| Risk | 1 | 2016 | 5288 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4545 | 0.07 | Why? |
| Proportional Hazards Models | 1 | 2016 | 6543 | 0.07 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.06 | Why? |
| Free Radicals | 1 | 2003 | 55 | 0.06 | Why? |
| NADH Dehydrogenase | 2 | 2013 | 9 | 0.06 | Why? |
| Arthritis, Rheumatoid | 1 | 2017 | 2043 | 0.06 | Why? |
| Catalase | 1 | 2003 | 97 | 0.06 | Why? |
| Photosynthesis | 2 | 2013 | 38 | 0.06 | Why? |
| Superoxide Dismutase | 1 | 2003 | 155 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Nedd4 Ubiquitin Protein Ligases | 1 | 2021 | 43 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2019 | 5837 | 0.06 | Why? |
| Lopinavir | 1 | 2016 | 4308 | 0.06 | Why? |
| Endosomal Sorting Complexes Required for Transport | 1 | 2021 | 67 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.06 | Why? |
| Pyridones | 2 | 2017 | 738 | 0.06 | Why? |
| Italy | 3 | 2020 | 38444 | 0.05 | Why? |
| Fear | 1 | 2016 | 3607 | 0.05 | Why? |
| Coinfection | 2 | 2017 | 6820 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.05 | Why? |
| Ubiquitination | 1 | 2021 | 343 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Child | 2 | 2020 | 70012 | 0.05 | Why? |
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2018 | 31 | 0.05 | Why? |
| Proviruses | 1 | 2018 | 82 | 0.04 | Why? |
| Sclerosis | 1 | 2017 | 26 | 0.04 | Why? |
| Neocortex | 1 | 2017 | 17 | 0.04 | Why? |
| Smad Proteins | 1 | 2017 | 19 | 0.04 | Why? |
| Aged | 6 | 2021 | 215776 | 0.04 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Zebrafish | 1 | 2018 | 181 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Tablets | 1 | 2018 | 219 | 0.04 | Why? |
| Mozambique | 1 | 2017 | 205 | 0.04 | Why? |
| Temporal Lobe | 1 | 2017 | 83 | 0.04 | Why? |
| Caspase 1 | 1 | 2017 | 149 | 0.04 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.04 | Why? |
| Pharmacogenetics | 1 | 2017 | 222 | 0.04 | Why? |
| Preliminary Data | 1 | 2017 | 457 | 0.04 | Why? |
| Anal Canal | 1 | 2018 | 367 | 0.04 | Why? |
| Adaptation, Physiological | 1 | 2018 | 359 | 0.04 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2017 | 536 | 0.03 | Why? |
| Mental Disorders | 1 | 2017 | 6742 | 0.03 | Why? |
| Phycobiliproteins | 1 | 2013 | 1 | 0.03 | Why? |
| Electron Probe Microanalysis | 1 | 2013 | 2 | 0.03 | Why? |
| Statistics, Nonparametric | 1 | 2017 | 1008 | 0.03 | Why? |
| Mammary Neoplasms, Experimental | 1 | 1973 | 21 | 0.03 | Why? |
| Gene Frequency | 1 | 2019 | 1210 | 0.03 | Why? |
| Antioxidants | 2 | 2018 | 1593 | 0.03 | Why? |
| Chloroplasts | 1 | 2013 | 38 | 0.03 | Why? |
| Chlorophyll | 1 | 2013 | 34 | 0.03 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.03 | Why? |
| Cell Wall | 1 | 2013 | 62 | 0.03 | Why? |
| Biomass | 1 | 2013 | 80 | 0.03 | Why? |
| Fibrosis | 1 | 2017 | 800 | 0.03 | Why? |
| Carotenoids | 1 | 2013 | 70 | 0.03 | Why? |
| Alleles | 1 | 2019 | 1557 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.03 | Why? |
| Indoles | 1 | 2021 | 1243 | 0.03 | Why? |
| Neuropsychological Tests | 1 | 2017 | 954 | 0.03 | Why? |
| Anticonvulsants | 1 | 2017 | 634 | 0.03 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.03 | Why? |
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 581 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2018 | 1136 | 0.03 | Why? |
| Cytoplasm | 1 | 2013 | 304 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Databases, Genetic | 1 | 2017 | 1127 | 0.03 | Why? |
| Retrospective Studies | 3 | 2018 | 105322 | 0.03 | Why? |
| Embryo, Nonmammalian | 1 | 2010 | 36 | 0.03 | Why? |
| Mitosis | 1 | 2010 | 43 | 0.03 | Why? |
| Electroencephalography | 1 | 2017 | 1242 | 0.03 | Why? |
| Mice, Inbred BALB C | 1 | 2021 | 5814 | 0.03 | Why? |
| RNA, Viral | 4 | 2018 | 32276 | 0.02 | Why? |
| Fresh Water | 1 | 2010 | 59 | 0.02 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.02 | Why? |
| Microscopy | 1 | 2013 | 414 | 0.02 | Why? |
| Sulfhydryl Compounds | 1 | 2010 | 104 | 0.02 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.02 | Why? |
| Base Sequence | 1 | 2017 | 3581 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.02 | Why? |
| Meglutol | 1 | 2008 | 1 | 0.02 | Why? |
| Valerates | 1 | 2008 | 4 | 0.02 | Why? |
| Protein Carbonylation | 1 | 2008 | 23 | 0.02 | Why? |
| Superoxides | 1 | 2008 | 36 | 0.02 | Why? |
| Oxidants | 1 | 2008 | 72 | 0.02 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.02 | Why? |
| Sequence Analysis, RNA | 1 | 2017 | 2290 | 0.02 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.02 | Why? |
| Carbon Radioisotopes | 1 | 2007 | 35 | 0.02 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.02 | Why? |
| Genetic Variation | 1 | 2020 | 3919 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Adenocarcinoma | 1 | 1973 | 651 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Glutathione | 1 | 2008 | 280 | 0.02 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.02 | Why? |
| Kidney Diseases | 1 | 2017 | 1434 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Risk Factors | 3 | 2019 | 71621 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2018 | 4002 | 0.02 | Why? |
| Creatine Kinase | 1 | 2007 | 386 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Environment | 1 | 2010 | 769 | 0.02 | Why? |
| Muscle Weakness | 1 | 2007 | 406 | 0.02 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.02 | Why? |
| Molecular Structure | 1 | 2008 | 1539 | 0.02 | Why? |
| Young Adult | 3 | 2018 | 93724 | 0.01 | Why? |
| Age Factors | 1 | 2003 | 21039 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.01 | Why? |
| Carbon Dioxide | 1 | 2007 | 917 | 0.01 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.01 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.01 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Antibodies, Neoplasm | 1 | 1973 | 15 | 0.01 | Why? |
| Methods | 1 | 1973 | 19 | 0.01 | Why? |
| Cell Division | 1 | 1973 | 136 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Cell- and Tissue-Based Therapy | 1 | 1973 | 422 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2007 | 10998 | 0.01 | Why? |
| Cell Survival | 1 | 1973 | 1581 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2019 | 51949 | 0.00 | Why? |
| Pregnancy | 1 | 2007 | 23879 | 0.00 | Why? |
| Epitopes | 1 | 1973 | 4113 | 0.00 | Why? |
| Immunity, Cellular | 1 | 1973 | 3614 | 0.00 | Why? |